Study sample collection protocol for analysis by EarlyGuardTM of serum miRNA from women referred for additional testing due to abnormal breast imaging classified as BI-RADS® 3, 4 or 5.


By drawing a tube of blood, data is obtained that will hopefully improve the breast cancer screening process in the future. Researchers are looking at serum miRNA signatures to determine if a subsequent breast biopsy has a higher likelihood of being positive or negative. This study is recruiting patients who have breast imaging studies suspicious for cancer discovered during screening.

Principal Investigator



Overlake Medical Center
1035 116th Ave NE 
Bellevue, WA 98004

Phone: (425) 688-5000